-
公开(公告)号：US20200206222A1
公开(公告)日：2020-07-02
申请号：US16717080
申请日：2019-12-17
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Dominic REYNOLDS , Ming-Hong HAO , John WANG , Sudeep PRAJAPATI , Takashi SATOH , Anand SELVARAJ
IPC: A61K31/505 , A61K31/5377 , A61K31/506
Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
-
公开(公告)号：US20210299269A1
公开(公告)日：2021-09-30
申请号：US17059635
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong Xiao
IPC: A61K47/68 , C07K16/32 , C07K16/28 , C07K16/40 , A61K47/60 , C07D405/06 , A61P35/00 , G01N33/50 , C07D313/00 , A61K31/496 , A61K31/365 , A61K39/395 , A61K45/06 , A61K39/00 , A61K9/127 , A61K9/51 , C12Q1/6886 , G01N33/574 , C07K16/30 , C07K16/24
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20210177837A1
公开(公告)日：2021-06-17
申请号：US17046528
申请日：2019-04-11
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Andrew COOK , Dominic REYNOLDS , Cheng ZHONG , Ryan BRAWN , Shelby ELLERY , Thiwanka SAMARAKOON , Xiang LIU , Sudeep PRAJAPATI , Megan SHEEHAN , Jason T. LOWE , James PALACINO
IPC: A61K31/496 , A61K9/00 , A61K39/395 , A61K38/21 , A61K38/20 , A61K38/19 , C07D313/00 , C07D405/06 , C07D405/10 , C07D405/12 , C07D413/14 , C07D498/08 , C07D491/107 , C07D407/12 , C07D417/10 , C07D413/10 , C07D487/04 , C07D453/02 , C07D405/14 , C07D413/12 , C07D409/12 , C07D471/10 , A61K31/5377 , A61K31/497 , A61K31/541 , A61K31/506 , A61K31/551 , A61K31/5386 , A61P35/00
Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy.
-
公开(公告)号：US20240368140A1
公开(公告)日：2024-11-07
申请号：US18582548
申请日：2024-02-20
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Gregg F. KEANEY , John WANG , Baudouin GERARD , Kenzo ARAI , Xiang LIU , Guo Zhu ZHENG , Kazunobu KIRA , Lisa A. MARCAURELLE , Marta NEVALAINEN , Ming-Hong HAO , Morgan Welzel O'SHEA , Parcharee TIVITMAHAISOON , Sudeep PRAJAPATI , Tuoping LUO , Nicholas C. GEARHART , Jason T. LOWE , Yoshihiko KOTAKE , Satoshi NAGAO , Regina Mikie KANADA SONOBE , Masayuki MIYANO , Norio MURAI , Andrew COOK , Shelby ELLERY , Atsushi ENDO , James PALACINO , Dominic REYNOLDS
IPC: C07D407/06 , A61K45/06 , A61P35/00 , C07D313/00 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/08 , C07D487/10 , C07D491/107
Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
-
公开(公告)号：US20240360108A1
公开(公告)日：2024-10-31
申请号：US18581307
申请日：2024-02-19
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC classification number: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
Patent Agency Ranking
公开(公告)号：US20210101888A1
公开(公告)日：2021-04-08
申请号：US17247117
申请日：2020-11-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC: C07D405/12 , A61P35/00
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20170360785A1
公开(公告)日：2017-12-21
申请号：US15627851
申请日：2017-06-20
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Dominic REYNOLDS , Ming-Hong HAO , John WANG , Sudeep PRAJAPATI , Takashi SATOH , Anand SELVARAJ
IPC: A61K31/505 , C07D405/12 , C07D403/12 , C07D401/12 , C07D239/48 , C07C53/18 , A61K31/5377 , C07D413/12 , A61K31/506
Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
-
公开(公告)号：US20170007601A1
公开(公告)日：2017-01-12
申请号：US15221018
申请日：2016-07-27
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Dominic REYNOLDS , Ming-Hong HAO , John WANG , Sudeep PRAJAPATI , Takashi SATOH , Anand SELVARAJ
IPC: A61K31/505 , A61K31/5377 , G01N33/574 , A61K31/506
CPC classification number: A61K31/505 , A61K31/506 , A61K31/5377 , C07C53/18 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
Abstract translation: 本文提供了可用作FGFR4抑制剂的式I化合物，以及其用途的方法。
-
公开(公告)号：US20250135017A1
公开(公告)日：2025-05-01
申请号：US18830446
申请日：2024-09-10
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC: A61K47/68 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61P35/00 , C07D313/00 , C07D405/06 , C07D405/12 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.
-
公开(公告)号：US20230301990A1
公开(公告)日：2023-09-28
申请号：US18180063
申请日：2023-03-07
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Andrew COOK , Dominic REYNOLDS , Cheng ZHONG , Ryan BRAWN , Shelby ELLERY , Thiwanka SAMARAKOON , Xiang LIU , Sudeep PRAJAPATI , Megan SHEEHAN , Jason T. LOWE , James PALACINO
IPC: A61K31/496 , A61P35/00 , A61K9/00 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/395 , C07D313/00 , C07D405/06 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08
CPC classification number: A61K31/496 , A61P35/00 , A61K9/0053 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/191 , A61K38/2013 , A61K38/2066 , A61K38/208 , A61K38/2086 , A61K38/217 , A61K39/3955 , C07D313/00 , C07D405/06 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08 , C07B2200/05
Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.023 seconds)
